Novartis to scale up data science under AI deal with Oxford
Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Oxford's Big Data Institute (BDI) will use artificial intelligence to analyze ultra large and multiple data sets from Novartis' drug development programs to identify early predictors of patient response to treatments.
Under the five-year deal, the partners will apply BDI's statistical machine learning technology and advanced analytics to anonymized data from Novartis' clinical trials as well as from about 5...
Read the full 322 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
$50 USD
